TAS 116

Drug Profile

TAS 116

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastrointestinal stromal tumours
  • Phase I Solid tumours

Most Recent Events

  • 08 Sep 2017 Efficacy and safety data from a phase II trial in Gastrointestinal stromal tumours presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 02 Jun 2017 Adverse events, efficacy, pharmacokinetics, pharmacodynamics data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 01 Feb 2016 Phase-II clinical trials in Gastrointestinal stromal tumours (Late-stage disease, Second-line therapy or greater) in Japan (PO) (JapicCTI163182)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top